The aim of this study was to investigate feasibility, tolerability and efficacy of rituximab-supplemented high-dose sequential chemotherapy (R-HDS) with peripheral blood progenitor cell autografting as frontline or salvage treatment in patients with advanced non-Hodgkin's lymphoma (NHL). Thirty-two patients have been treated: 14 at disease onset and 18 with relapsed or progressive disease. R-HDS regimens included six courses of rituximab. Rituximab was delivered either concurrently with high-dose chemotherapy to exploit the in vivo purging properties of the drug as well as at the end of the treatment plan to target minimal residual disease. All patients treated at disease onset completed their treatment with no life-threatening toxicity, while two toxic deaths due to severe bilateral pneumonia were observed among patients treated due to relapsed or refractory disease. Thirteen of 14 patients treated up-front achieved CR. Among pre-treated patients 10 of 18 achieved CR with better results in patients with relapsed (seven of eight) compared to progressive disease (three of 10). PCR analysis was carried out in indolent lymphoma patients: nine of nine follicular lymphomas and three of six CD5-positive NHL collected PCR-negative peripheral blood progenitor cell harvests. The results of this pilot study show that R-HDS is feasible and effective with acceptable toxicity when used at disease onset. In pretreated patients this treatment also showed promising results, although the risk of severe infections needs to be considered. Leukemia (2001Leukemia ( ) 15, 1941Leukemia ( -1949 
Introduction
Intensified chemotherapy with autologous transplantation has been shown to be an effective treatment strategy for the management of both indolent and aggressive non-Hodgkin's lymphomas (NHL) at relapse. [1] [2] [3] [4] [5] [6] [7] [8] [9] The role of high-dose therapy early in the disease course is more controversial and conflicting results have been observed among the most recently published trials. [10] [11] [12] [13] [14] [15] [16] [17] It should be noted that most failures in the autologous transplantation setting are associated with disease relapses rather than with toxic episodes. 3, 18 These relapses may originate either from the presence of contaminating tumor cells in stem cell products collected for rescue, 19, 20 and/or from in vivo persistence of lymphoma cells capable of surviving despite delivery of high-dose chemotherapy. 21 Thus, there is a clear interest in improving the results obtained with such regimens by combining them with agents that effectively clear stem cell harvests from contaminating tumor cells and target minimal residual disease (MRD) through mechanisms different from those associated with chemotherapy-induced tumor cell killing.
There are several non-chemotherapeutic options that are under extensive evaluation for the treatment of NHL patients. [22] [23] [24] [25] Among them, humanized and chimeric monoclonal antibodies [26] [27] [28] [29] [30] [31] and particularly the anti-CD20 antibody rituximab [32] [33] [34] [35] [36] [37] [38] [39] [40] have received special attention. This is due to several attractive properties of monoclonal antibodies such as: (1) absence of severe systemic toxicity, in particular myelotoxicity; 33, 38 (2) administration on an outpatient basis, 32, 34 (3) possibility of being effectively combined with conventional chemotherapy; 37, 40 (4) significant activity both on indolent and aggressive lymphomas. 35, 36, 39 Based on these features, rituximab may represent an ideal drug to be combined with intensified chemotherapeutic approaches in order to obtain tumor-free stem cell harvests and to effectively treat MRD.
Two recent studies have evaluated the effectiveness of this combination in eradicating PCR-detectable disease. 41, 42 Both studies showed that the combination of rituximab and highdose chemotherapy induced significant in vivo purging effect and allowed the collection of stem cells with no PCR-detectable disease in the majority of patients with follicle-center (FCL) and mantle-cell lymphoma (MCL). In addition, the high rate of complete remissions (CR) obtained in these studies suggested that rituximab might potentiate the anti-tumor effect of high-dose chemotherapy. However, these studies were mainly focused on PCR results and provided few or no data on feasibility and toxicity. In particular, there is a very limited experience on the concurrent administration of rituximab and highdose (R-HDS) chemotherapy and it is still unclear whether this therapeutic option should be preferentially used at disease onset or as salvage treatment.
Since 1997, at our institutions we have supplemented the high-dose sequential (HDS) chemotherapy approaches currently employed to treat patients with both indolent and aggressive lymphoma with rituximab. Our schedule was characterized by rituximab delivery prior to stem cell mobilization in order to obtain an 'in vivo purging' effect. Two additional rituximab courses were then given following autologous transplantation in an effort to eradicate any potential persistence of residual lymphoma cells. To date, 32 patients have been treated. This combination proved safe and effective when used at disease onset in both indolent and aggressive lymphomas. Notably, among patients treated in more advanced disease phases, two fatal toxic episodes were observed. However, effectiveness, at least in patients with relapsed disease, was satisfactory. These results indicate that R-HDS: (1) is feasible and allows collection of adequate peripheral blood progenitor cells (PBPC) in the vast majority of patients; (2) has a high anti-tumor activity in patients treated frontline and in relapsed disease; (3) eradicates PCR-detectable disease in stem cell harvests and at post-autograft followup in most patients; (4) it might show increased toxicity when delivered to patients with relapsed/refractory disease.
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Materials and methods
Patient characteristics
Between February 1997 and January 2000, 32 patients (median age 41 years) entered a study program aimed to evaluate R-HDS in high-risk NHL. Eligibility criteria included: (1) age between 15 and 60 years old; (2) biopsy-proven diagnosis of B cell, CD20-positive NHL with the exception of lymphoblastic and Burkitt's lymphoma; (3) poor prognostic features at presentation were required for patients at disease onset. These consisted of an age adjusted IPI score у2 43, 44 or, exclusively for FCL patients, an Italian Lymphoma Intergroup (ILI) score у3; 45 (4) for patients with progressive disease no specific adverse prognostic factors were required. Patients with relapsed disease were also eligible, provided that recurrence occurred following a previous autograft or within 6 months of conventional therapy; (5) no previous monoclonal antibody treatment; (6) negative HBsAg, HCV and HIV testing; (7) no evidence of any associated neoplasm other than fully resected cervix cancer or non-melanoma skin cancer. Patients showing evidence of central nervous system involvement were not excluded from the study. All patients gave written informed consent to the study program and our Institutional Review Board approved the study.
Fourteen patients were treated at disease onset, eight were at disease relapse and 10 had progressive disease following first-line conventional chemotherapy (Table 1) . Main patient characteristics at study entry are summarized in Table 1 . For patients with relapsed or progressive disease, clinical characteristics at disease onset and previous treatments are summarized in Table 2 . Sixteen patients had indolent NHL (three small lymphocytic lymphoma (SLL), 13 FCL, four had MCL, 12 diffuse large cell lymphoma (DLCL) (three with evidence of transformed histology) ( Table 1 ). Based on the common features of low chemosensitivity and very uncommon achievement of molecular and clinical complete remission MCL and SLL patients were grouped for clinical and molecular response analysis and were defined as CD5-positive NHL. BM involvement was detectable at study entry in 19 patients: 14 indolent lymphomas, three MCL and two DLCL with transformed histology. Bulky disease was observed in 10 patients with indolent lymphoma, three with MCL and 11 with DLCL (Table 1) . Leukemic disease (peripheral blood lymphocytes Ͼ12 000) before treatment with R-HDS was observed in five patients.
Treatment protocol
Three different rituximab-supplemented HDS schedules were used; these are shown schematically in Figure 1 . All these regimens were originally designed as rituximab-free schedules specifically tailored for the various lymphoma subtypes and proved feasible with acceptable toxicity when delivered without monoclonal antibody supplementation. [46] [47] [48] Only minor modifications have been introduced to the R-HDS regimens compared to rituximab-free schedules. These modifications are detailed below.
In patients with indolent lymphoma (SLL, FCL) at disease onset the backbone of the intensified HDS regimen 47 ( Figure 1a ) has been modified as follows (R-HDSi): (1) methotrexate 8 g/m 2 has been omitted; (2) two infusions of rituximab 375 mg/m 2 were scheduled during the 50 days chemotherapyfree interval. Two more rituximab courses were administered with an in vivo purging intent on day +2 following cyclophosphamide 7 g/m 2 and the day preceding stem cell harvesting. Finally, two rituximab courses were delivered on days +30 and + 37 following autografting.
In patients with relapsed/progressive disease, regardless of their histological subtype, we used a treatment schedule similar to that employed by Magni et al 42 (R-HDSc) (Figure 1b ). After an initial debulkying with 2 APO (or two DHAP) courses, HDS chemotherapy was delivered as follows: cyclophosphamide 7 g/m 2 day +1, followed by rituximab 375 mg/m 2 day +2 and the day preceding stem cell harvesting. PBPC collections were performed with the aim of collecting at least 10 × 10 6 CD34-positive cells/kg. Within 21 days from the previous course, Ara-C 2 g/m 2 twice a day was delivered for 6 days followed by a stem cell support of 2 × 10 6 CD34-positive cells/kg on day +7 and by the infusion of rituximab 375 mg/m 2 on day +8 and at hematopoietic recovery. At neutrophil recovery, PBPC cells were again collected whenever patients had overt bone marrow involvement at study entry or failed to collect enough PBPC following high-dose cyclophosphamide. In patients with overt bone marrow involvement at diagnosis, PBPC cells obtained after Ara-C were the preferred stem cell source for autologous transplantation. The two myeloablative regimens consisted of melphalan 180 mg/m 2 and mitoxantrone 60 mg/m 2 + melphalan 180 mg/m 2 . Both regimens were followed by the infusion of at least 4 × 10 6 CD34-positive cells/kg. On days +30 and +37 following the second autografting course, two additional courses of rituximab 375 mg/m 2 were administered.
For DLCL at disease onset we reasoned that based on the good results obtained with a single autografting we could not offer to these patients a treatment schedule including a double myeloablative regimen. We thus decided to modify the RHDSc schedule by substituting the first autograft (melphalan 180 mg/m 2 ) with a less myelotoxic regimen consisting of etoposide 2.4 g/m 2 day +1 + cisplatin 100 mg/m 2 day +2 (Figure 1c ). This course was delivered with a stem cell support of 2 × 10 6 CD34-positive cells/kg on day +4. This program has been defined as R-HDSc-red.
Prophylactic measures were those currently used for patients enrolled in HDS chemotherapy regimens. Pneumocystis carinii prophylaxis with cotrimoxazole 960 mg twice a day was administered p.o. twice a week when the patient was under steroid treatment and for 180 days following autologous transplantation. Oral fluconazole 100 mg and ciprofloxacin 500 mg twice a day were always administered when absolute neutrophil counts were lower than 0.5 × 10 9 /l. Oral acyclovir 400 mg three times a day or i.v. 250 mg three times a day was administered from day +4 to day +120 following each myeloablative course. In addition, following the first rituximab infusion, patients were assessed for their IgG serum levels twice a month and human i.v. immunoglobulins were administered at the dosage of 0.4 g/kg when IgG levels were below normal values. Following each high-dose course and following autologous transplantation, patients were monitored for complete blood count and biochemistry at least three times a week until hematopoietic recovery. Screening for CMV antigenemia was performed at least twice a month from the beginning of the HDS phase until day +100 following autologous transplantation.
Blood cell counts and number of circulating CD34-positive cells were monitored daily starting from day +9 following high-dose cyclophosphamide and from day +15 following high-dose Ara-C (when required) to predict number and timing of leukaphereses, according to previously published pro- cedures. 49 Leukaphereses were performed when WBC counts were at least 1000/l and CD34-positive cells Ͼ10/l.
Minimal residual disease assessment
In patients with FCL, SLL and MCL, in which the collection of PCR-negative harvests and the achievement of a PCR-negative status following autologous transplantation has a well defined prognostic value, 21 ,50-53 we attempted to obtain a molecular marker suitable for PCR analysis. The Bcl-2 rearrangement was initially searched in FCL and the Bcl-1 rearrangement in MCL. These rearrangements were amplified using the nested PCR approaches previously described. 21, 54 Bcl-2-negative FCL patients, Bcl-1-negative MCL patients and all SLL patients were then screened for the immunoglobulin heavy chain (IgH) rearrangement according to the method described by Voena et al. 52 This has been performed in order to obtain a tumor marker also for patients lacking a PCR-amplifiable translocation. MRD analysis was performed on all available PBPC harvests, on BM samples prior to autologous transplantation and 3 months after completion of the program.
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Evaluation of patients Response assessment:
Clinical response was assessed by full restaging at the end of the HDS phase and at 3 months after autograft and thereafter at 6 month intervals for the subsequent years. Response was evaluated according to Cheson et al. 55 All patients started on treatment were considered evaluable for response. The closing date for analysis was 1 December 2000.
Results
Treatment feasibility
As shown in Table 3 , all but one patient treated frontline collected the required amount of PBPC with a median number of one leukapheresis (range 1-4). Poor mobilization of PBPC harvests was observed only in one FCL patient (Pt 16). This patient was successfully autografted using BM cells. Patients with progressive/relapsed disease underwent a median of four leukaphereses (range 1-7) to collect enough PBPC for com- pleting their planned treatment schedule. One SLL patient refused to undergo the final autografting phase while she was in PR at the end of the high-dose sequential phase.
Toxicity of R-HDS
Among the 14 patients treated with R-HDS at disease onset no treatment-related deaths were observed. In contrast, two toxic deaths (Pt 9 and Pt 21) were observed among patients treated for relapsed/progressive disease (Table 4) . Both patients died following the myeloablative phase due to bilateral pneumonia. In Pt 21 the etiology was defined to be Aspergillosis at post-mortem examination. This patient died on day +38 following the first myeloablative course. It should be noted that fungal pneumonia progressed despite treatment with liposomal i.v. amphotericin B. The patient was in CR at the time of restaging before autografting. Pt 9 developed diffuse interstitial pneumonia and died on day +45 following the second myeloablative course, despite treatment with broadspectrum antibacterial drugs, i.v. amphotericin B and gancyclovir. No etiological agent could be identified at autopsy. Although this patient was in partial remission (PR) before the second myeloablative regimen, no sign of lymphoma could be detected at autopsy. Other infectious episodes included non-fatal pneumonia observed in five patients and viral reactivation in 11 patients. Viral reactivation was due to CMV in five patients and due to VZV in six patients. CMV reactivation was usually detected when asymptomatic due to the strict monitoring of this condition performed at our Institution. Occasionally, CMV reactivation was associated with pancytopenia. No patients developed CMV pneumonia or other severe manifestations of CMV disease. All patients cleared antigenemia with short courses of gancyclovir (5 g/kg twice a day for 7 days) associated with infusions of i.v immunoglobulins (0.4 g/kg monthly). VZV reactivations were always localized and acyclovir treatment was successful in all cases.
Oral mucositis during the myeloablative phase was the most frequent non-hematological toxicity as typically happens also for patients treated with rituximab-free HDS treatments. The side-effects usually associated with rituximab infusions were remarkably uncommon in this patient series (only Pt 27 had rigors, fever and hypothension). This is probably due to the intense chemotherapeutic debulkying performed before the first rituximab infusion. To date, no late toxic effects have been detected with the exception of one case of heart failure in a DLCL patient (Pt 4). In particular, no second tumors have so far been detected, although follow-up is short for this complication.
Response to treatment and outcome
At the end of the whole program, 23 of 32 patients achieved CR, one achieved PR, six had progressive disease (five with nodal and/or medullary disease and one with central nervous system disease) and two died of treatment-related toxicity while in CR, as previously described (Table 4) . Thirteen of 14 patients treated up-front achieved CR (five of five DLCL, seven of seven FCL and one of two CD5-positive lymphomas). Ten of 18 patients with relapsed/progressive disease achieved CR. In particular, CR was achieved by four of six FCL, three of seven DLCL and three of five CD5-positive lymphomas. Notably, CR was achieved by three of 10 patients with progressive disease and by seven of eight patients treated due to relapsed disease (Table 3) .
Median follow-up of this panel of patients is 14 months (range 6-46). Only one relapse has been observed among patients achieving CR (Pt 3). The patient with CLL/SLL achieving PR (Pt 30), who did not undergo autologous transplantation, relapsed 14 months after the end of treatment. All but one patient with progressive disease following R-HDS chemotherapy died shortly after evidence of disease progression.
Minimal residual disease evaluation
MRD analysis has been performed on patients with FCL or CD5-positive lymphoma (Table 5) . Eighteen patients had adequate tumor tissue at study entry, while unfortunately this was not available for two patients (Pt 24 and Pt 25). In 15 of 18 patients a PCR-amplifiable tumor-specific marker was available (Bcl-1 in one patient, Bcl-2 in six patients and IgH rearrangement in eight patients) ( Table 5 ). Sensitivity of our PCR assays was 10
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. Molecular analysis was carried out on PBPC harvests and on BM samples. As previously mentioned, patients treated with the R-HDSi regimen underwent one single mobilization course at the end of the HDS sequence while patients treated with R-HDSc underwent tandem mobilization (defined as initial and final course). Thus, in eight patients treated with this regimen, PBPC harvests from two mobilization courses were available for PCR analysis. BM samples were analyzed both prior to and following autografting.
Results of PCR analysis on PBPC harvests have been reported in Table 5 . All FCL patients achieved eradication of PCR-detectable disease at least in a proportion of their stem cell collections. At the end of the program all FCL patients achieving CR turned out to be in molecular remission also (Table 5) . Pt 20 could not be evaluated at the end of treatment due to rapid disease progression. In contrast, only three of six CD5-positive lymphomas had some stem cell collections that were free of PCR-detectable disease. Also three patients with CD5-positive lymphoma achieving CR at the end of the program turned out to be PCR-negative. The patient who refused to undergo autologous transplantation (Pt 30) remained PCRpositive at repeated follow-up examinations (Table 5) . Interestingly, in four patients (Pt 20, Pt 21, Pt 27, Pt 32), collections were PCR-positive following the preliminary mobilization course and PCR-negative following the final mobilization course suggesting an in vivo purging effect of repeated courses of rituximab-supplemented HDS chemotherapy. Three patients (Pt 15, Pt 23, Pt 31) had PCR-positive pre-transplant BM and converted to molecular remission following autografting. Of note, we observed evidence of progressive disease at lymph node level in two patients treated for progressive disease despite the fact that their stem cell collections had no PCR-detectable disease (Pt 20, Pt 27).
Discussion
In the present study we evaluated feasibility, toxicity and efficacy of R-HDS regimens for the treatment of patients with both indolent and aggressive NHL. R-HDS regimens proved feasible in all patients. Toxicity was acceptable in patients treated at disease onset, while it appeared to be more pronounced when R-HDS regimens were delivered to patients with relapsed or progressive disease. CR were frequently achieved both in patients treated frontline (13 of 14) and in those with relapsed disease (seven of eight). Also, the achievement of CR in three of 10 patients treated due to progressive disease was encouraging. In addition, all patients with FCL lymphoma and three of five patients with CD5-positive non-Hodgkin's lymphoma collected PCR-negative PBPC harvests and a high proportion achieved molecular remission at the end of the program. These results compare favorably with previous reports of patients treated with rituximab-free HDS regimens. 47, 56, 57 Taken together, these data suggest that R-HDS regimens are promising therapeutic options that deserve further investigation.
Despite advances in the treatment of NHL, several subgroups of patients still have a dismal outcome when treated with conventional treatments and thus there is a need for innovative strategies. Poor prognostic features characterized all the patients included in this study. Based on current knowledge, chances of cure for this patient population using a conventional approach would have been minimal or even absent. We thus decided to attempt to potentiate the HDS regimens by the addition of rituximab. Although rituximab can be safely associated with conventional chemotherapy such as CHOP, 37, 40 little data are available to date on the safety of rituximab when combined with intensified regimens such as HDS. Our results indicate that R-HDS is a feasible treatment option. All but one patient collected enough PBPC to perform the autografting phase. This patient completed the program since adequate amounts of BM cells could be collected. Thus, considering one refusal and two toxic deaths, 90% of patients successfully completed the program.
Toxicity was another major concern in this setting, mostly due to the potential risk of delivering intensified chemotherapy to patients with a deeply impaired B cell function. Our data show that the monoclonal antibody supplementation of HDS chemotherapy is safe when delivered at disease onset. The same treatment proved to be feasible also for pre-treated patients although the risk of severe infections should not be underestimated in this setting. Indeed, in this subset of patients, severe toxic episodes were observed despite generous prophylaxis with i.v. human immunoglobulins. This may potentially be related to a defective production of secretory IgA that cannot be restored by immunoglobulin infusion and may explain the occurrence of severe lung infections. 58, 59 Based on these results, in high-risk patients we now favor the use of R-HDS regimens as frontline treatment. However, based on the good response rates and taking into account the potential risk of delivering any kind of chemotherapy to patients with progressive or relapsed disease, we believe that salvage treatment with R-HDS is an interesting option that should be further evaluated in large possibly multicentric trials. An additional concern derives from the observation of a high incidence of CMV and VZV reactivation. To our knowledge, CMV and VZV reactivation have never been described as frequent events in other populations of rituximab-treated patients, including those receiving it in combination with conventional chemotherapy. In addition, the incidence seemed to be higher compared to that previously observed using rituximab-free HDS regimen (among 150 patients treated with rituximab-free HDS regimens we observed two CMV and one VZV reactivation: ie 2% vs 34%; P Ͻ 0.005) (Tarella et al, unpublished observation). These findings suggest that patients treated with R-HDS might have a greater impairment of their immune function compared to those treated with rituximabfree autografting programs or with conventional chemotherapy associated with rituximab. Further investigation is probably needed from both the biological and clinical point of view to definitely assess these issues. However, it should be noted that careful monitoring and prompt treatment were always successful in preventing evolution towards severe viral disease. Thus, viral reactivation should not be regarded as a major obstacle to delivery of R-HDS regimens.
One potential alternative strategy for pre-treated patients is that of reducing the amount of chemotherapy, for example, by deleting or shortening the high-dose Ara-C course. This is undoubtedly worthy of further investigation, at least in patients with relapsed disease although we expect a significant loss of therapeutic effect especially in MCL patients, where Ara-C is considered one of the most effective drugs. 42 Indeed, we observed four patients treated with R-HDSc, whose PBPC collections were PCR-positive following rituximab-supplemented cyclophosphamide and converted to PCR negativity following rituximab-supplemented Ara-C. This finding strongly supports the therapeutic role of Ara-C in this patient population. A similar result has also been observed by Magni et al 42 in their recent article. Although our patient sample does not allow definitive conclusions on the effectiveness of R-HDS regimens to be drawn, both clinical and molecular results seem to support the potential therapeutic benefit of combining rituximab with HDS chemotherapy. Previously published reports on intensified chemotherapy in indolent lymphomas indicate that molecular remission can be obtained in approximately 50% FCL patients 56, 57 and in less than 10% CD5-positive lymphoma patients. 21, 60, 61 At our laboratory we obtained very similar results in a sample of 96 patients uniformly treated with rituximab-free HDS regimens (Ladetto et al, unpublished observation) . In contrast, nine of nine FCL and three of six patients with CD5-positive lymphoma patients collected PCRnegative harvests and most of them achieved molecular remission following R-HDS regimens. A prolonged follow-up is clearly required to demonstrate that the achievement of PCR-negativity through rituximab-containing regimens has the same predictive value of PCR negativity achieved following rituximab-free autografting programs. However, there is little doubt that R-HDS is able to induce a more effective tumor cell clearance compared to the same regimen delivered without rituximab supplementation.
In conclusion, this preliminary experience shows that R-HDS represents a feasible, well-tolerated therapeutic option in NHL patients at disease onset. Further investigation is required to definitively assess the role of R-HDS regimens in the treatment of patients with advanced lymphoma. However, the high CR rate and the promising results of PCR analysis suggest that these regimens may probably improve the results so far obtained with rituximab-free autografting programs. To test this hypothesis three large multicenter trials have recently been launched to definitively assess the therapeutic impact of R-HDS regimens in FCL, MCL and DLCL patients.
